Context Therapeutics (CNTX) Interest Coverage Ratio (2020 - 2021)
Context Therapeutics' (CNTX) quarterly Interest Coverage Ratio came in at 9815.57 in Q4 2021, up 120550.99% year-on-year from N/an in Q4 2020, and up 889.35% quarter-over-quarter from 1243.51 in Q3 2021.
Context Therapeutics (CNTX) Interest Coverage Ratio (2020 - 2021) Analysis & Trends
Context Therapeutics has disclosed Interest Coverage Ratio across 2 years of filings, most recently posting 9815.57 for Q4 2021.
- Interest Coverage Ratio for Q4 2021 came in at 9815.57, up 120550.99% year-over-year; the trailing twelve-month figure through Sep 2022 was 46319.89 (up 223524.62% YoY), and the FY2021 annual result was 163.85, down 4112.11% from the prior year.
- Interest Coverage Ratio came in at 9815.57 for Q4 2021 at Context Therapeutics, up from 1243.51 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 9815.57 in Q4 2021 to a low of 1243.51 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 3.58 |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -258.33 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 11.50 |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 11.79 |
| 10 | Context Therapeutics | 166.57 Mn | 166.57 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 9,815.57 |
| Sep 30, 2021 | -1,243.51 |
| Mar 31, 2021 | -2.80 |
| Dec 31, 2020 | -8.15 |
| Sep 30, 2020 | -6.84 |